Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress

Rhea-AI Summary

Jaguar Health (NASDAQ:JAGX) family company Napo is a silver sponsor of the April 2-4, 2026 Elite Ped-GI Congress in Abu Dhabi and is supporting an investigator-initiated proof-of-concept study of crofelemer liquid in pediatric intestinal failure (IF) patients with MVID and SBS-IF.

The study reported parenteral support (PS) reductions of 12–37% in ongoing patients treated >1 year; an abstract on long-term safety and efficacy was submitted for ESPGHAN June 2026. The global SBS/IF market is estimated at $8.0 billion by 2033.

Positive

• Parenteral support reduction of 12–37% in POC study
• Patients on crofelemer treatment for more than one year
• Abstract submitted for ESPGHAN June 2026 presentation

Negative

• Results from an investigator-initiated proof-of-concept study (early-stage evidence)
• Long-term safety and efficacy data not yet publicly presented or peer-reviewed

Argus Apr 2 session

-1.48% close to close Open Argus

Details

News Market Reaction – JAGX

On Apr 2, the day this news came out, JAGX closed 1.48% below the previous close.

Data tracked by StockTitan Argus for the Apr 2 session.

Market Context

This announcement underscores Jaguar’s focus on crofelemer for pediatric intestinal failure, citing ...

Analysis

This announcement underscores Jaguar’s focus on crofelemer for pediatric intestinal failure, citing parenteral support reductions of 12–37% and targeting an SBS/IF market estimated at $8.0 billion by 2033. The company has recently communicated multiple crofelemer and financing milestones and holds an effective S‑3 shelf, giving flexibility for future offerings. Investors may monitor further data from the Abu Dhabi study, upcoming ESPGHAN presentations, and how new evidence integrates with Jaguar’s broader capital‑structure and listing challenges.

Key Figures

SBS/IF market size: $8.0 billion PS reduction range: 12–37% PS weekly frequency: Up to 7 days/week +2 more

SBS/IF market size

$8.0 billion

Estimated global market for SBS including IF by 2033

PS reduction range

12–37%

Parenteral support reduction in ongoing pediatric IF proof-of-concept study

PS weekly frequency

Up to 7 days/week

Frequency many intestinal failure patients require parenteral support

PS daily duration

20 hours or more/day

Daily duration some intestinal failure patients require parenteral support

Treatment duration

More than one year

Time patients in UAE study have received crofelemer treatment

Historical Context

5 past events · Latest: Mar 18

5 events

1. Mar 18

   Clinical trial update

   24h Move

   -8.0%

   FDA feedback supporting extension phase of pediatric crofelemer MVID trial.

2. Mar 16

   Preclinical partnership

   24h Move

   +0.7%

   JV Magdalena Biosciences starting preclinical coca study for appetite control.

3. Mar 11

   Investor presentation

   24h Move

   +20.0%

   CEO presenting near-term catalysts at Life Sciences Virtual Investor Forum.

4. Mar 09

   Balance sheet actions

   24h Move

   -16.9%

   Restructuring royalty and debt obligations and extinguishing 48,212 warrants.

5. Mar 03

   Non-dilutive funding

   24h Move

   -23.2%

   Securing additional $3M payment and highlighting future milestones from Future Pak deal.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

intestinal failure, microvillus inclusion disease, short bowel syndrome, parenteral support, +3 more

7 terms

intestinal failure medical

"Jaguar continues its sharp strategic focus on its global development program for crofelemer for rare-disease intestinal failure (IF) indications"

Intestinal failure is a medical condition in which the gut cannot absorb enough nutrients, fluids, or electrolytes to keep a person healthy, so they need long‑term medical support such as intravenous nutrition or specialized feeding tubes. Think of the intestines as a conveyor belt that breaks down and delivers fuel to the body; when it fails, ongoing treatments, surgeries, and chronic care services become necessary. For investors, this creates steady demand for therapies, medical devices, home infusion services and related regulatory approvals that can drive revenue and long‑term contracts.

microvillus inclusion disease medical

"all patients with microvillus inclusion disease (MVID) suffer from IF"

A rare, inherited condition in which the tiny, brush-like hairs on the inner lining of the small intestine are absent or abnormal, causing severe, lifelong diarrhea and inability to absorb nutrients. Think of the intestine’s surface as a shaggy carpet that helps soak up food; when those fibers are missing or disorganized, patients often need long-term intravenous feeding and specialized care. For investors, the disease matters because it creates clear demand for diagnostics, nutritional support, transplant solutions, and targeted therapies in the orphan-disease market.

short bowel syndrome medical

"as do a significant proportion of patients with short bowel syndrome (SBS)"

A chronic digestive disorder caused when a large portion of the small intestine is missing or not working, so the body cannot absorb enough nutrients and fluids from food. Investors should care because people with this condition often need long-term medical treatments, specialized nutrition or surgeries, and ongoing devices or drugs, creating sustained demand, higher healthcare costs, and opportunities for companies that provide therapies, supplies, or related services.

parenteral support medical

"demonstrating reductions in parenteral support (PS)"

Parenteral support is medical care that delivers nutrition, fluids or medications directly into a patient’s bloodstream or body tissues, bypassing the digestive system—think of it as feeding or hydrating someone through an IV rather than by mouth. Investors care because this service involves specialized products, durable revenue from long-term patient use, strict safety and reimbursement rules, and potential regulatory or supply risks that affect company earnings and growth.

total parenteral nutrition medical

"which consists of total parenteral nutrition (TPN) with supplemental intravenous fluids"

Total parenteral nutrition is a medical treatment that supplies all needed calories, fluids, vitamins and minerals directly into a patient’s bloodstream through an IV, bypassing the digestive tract — like a complete meal delivered by a drip. It matters to investors because TPN relies on specialized ingredients, preparation and delivery services with steady hospital and home-care demand, significant regulation and reimbursement exposure, and potential for durable revenue or risk from supply-chain or clinical issues.

proof-of-concept study technical

"supporting an independent investigator-initiated proof-of-concept study of crofelemer liquid formulation"

A proof-of-concept study is an early-stage test that checks whether a new drug, device, or treatment produces the intended effect in people or in lab models — like a pilot run to see if an idea actually works. For investors, its results are a key early signal: positive findings can greatly reduce uncertainty and boost a project’s value, while negative results often lead to delays, additional costs, or program termination.

ultrarare pediatric disease medical

"MVID has a lethal natural history and is an ultrarare pediatric disease"

An ultrarare pediatric disease is a medical condition that affects a very small number of children, often so few that standard tests and treatments are scarce. For investors, these diseases matter because developing a therapy is like addressing a tiny, specialized market: success can bring strong regulatory support, pricing power, and limited competition, but also higher clinical risk and uncertainty about long‑term demand and returns.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Jaguar continues its sharp strategic focus on its global development program for crofelemer for rare-disease intestinal failure (IF) indications; all patients with microvillus inclusion disease (MVID) suffer from IF, as do a significant proportion of patients with short bowel syndrome (SBS). The global market for SBS, including IF, is estimated to reach approximately $8.0 billion by 2033.

Near-term milestones for intestinal failure program buttressed by groundbreaking results of parenteral support reduction ranging from 12 to 37% in ongoing proof-of-concept study of crofelemer in pediatric IF patients; Abstract for long-term safety and efficacy of crofelemer liquid formulation submitted for presentation at ESPGHAN (European Society for Paediatric Gastroenterology Hepatology and Nutrition) Annual Meeting in 2026.

Click here to view video update from Jaguar CEO Lisa Conte on company's near-term catalysts.

SAN FRANCISCO, CA / ACCESS Newswire / April 2, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that it is a silver-level sponsor of the April 2-4, 2026 Annual ELITE PED-GI Congress in Abu Dhabi in the United Arab Emirates (UAE).

As previously announced, Napo is supporting an independent investigator-initiated proof-of-concept study of crofelemer liquid formulation in pediatric intestinal failure (IF) patients with in microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF) at Sheikh Khalifa Medical City in Abu Dhabi, UAE. The study's principal investigator, Dr. Mohamad Miqdady, previously presented an update on this study at the April 2025 ELITE PED-GI Congress, and patients participating in the study have continued to receive crofelemer treatment for more than one year.

Intestinal failure is a debilitating condition that often requires patients to receive life-sustaining fluids, electrolytes and nutrients through intravenous administration, which consists of total parenteral nutrition (TPN) with supplemental intravenous fluids, which together constitute PS. Many intestinal failure patients require PS up to 7 days a week, and sometimes for 20 hours or more per day. While crucial for intestinal failure patients, PS is associated with significant toxicities to patients, similar to some toxicities associated with chemotherapy, often causing serious health problems including infections, metabolic complications, and liver and kidney function problems. These symptoms may emerge at any time in intestinal failure patients and often become life-threatening. "Crofelemer has demonstrated groundbreaking benefit in pediatric IF patients in this study - demonstrating reductions in parenteral support (PS). MVID has a lethal natural history and is an ultrarare pediatric disease, and reduction of PS in MVID patients represents disease progression-modification," said Lisa Conte, Jaguar's president and CEO.

As announced, Dr. Miqdady conducted a presentation at the November 2025 North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting describing the initial groundbreaking results of the investigator-initiated trial in the UAE. Patients participating in the study have now been on crofelemer treatment for more than one year. An abstract to provide an update on the long-term safety and efficacy of crofelemer liquid formulation in pediatric IF patients with MVID and SBS, has been submitted to the ESPGHAN (European Society for Paediatric Gastroenterology Hepatology and Nutrition) Annual Meeting scheduled for June 2026 for consideration for a presentation. The global market for SBS, including IF, is estimated to reach approximately $8.0 billion by 2033.¹

The Annual Elite Ped-GI Congress is designed to provide information about high level, clinically significant updates and comprehensive trends relevant to the practice of pediatric gastrointestinal, nutrition and liver disorders. Dr. Miqdady serves as a member of Napo's Scientific Advisory Board. He is an American board-certified pediatric GI, hepatology and nutrition professor at Khalifa University in Abu Dhabi. He completed his Fellowship in Pediatric Gastroenterology at Baylor College of Medicine and Texas Children's Hospital in Houston.

About the Elite Ped-GI Congress

This Elite Ped-GI Congress is designed to provide information about high level, clinically significant updates and comprehensive trends relevant to the practice of pediatric gastroenterological, nutrition and liver disorders. The annual event provides a venue for healthcare professionals to share their best practices, to network within groups of interest, and to create and strengthen clinical collaborations. Additional information about the Elite Ped-GI Congress can be viewed here on the event website.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. Jaguar family companies Napo Pharmaceuticals (Napo) and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including MVID and short bowel syndrome.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit www.napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." These include statements regarding the expectation thatJaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

¹Global Short Bowel Syndrome Market - Size, Share, and Forecast (2025-2033)

CONTACT:
hello@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Jaguar Health (JAGX) announce at the April 2, 2026 Elite Ped-GI Congress?

They announced Napo's silver sponsorship and support for a crofelemer pediatric IF study. According to the company, the investigator-initiated trial in Abu Dhabi reported PS reductions of 12–37% and patients have received crofelemer for over one year.

How large were the reported parenteral support reductions in the JAGX crofelemer study?

The study reported parenteral support reductions ranging from 12% to 37%. According to the company, these results came from an ongoing proof-of-concept trial in pediatric IF patients with MVID and SBS-IF.

Has Jaguar Health (JAGX) published long-term crofelemer safety and efficacy data for pediatric IF?

Not yet; an abstract has been submitted to ESPGHAN for June 2026 consideration. According to the company, the abstract updates long-term safety and efficacy for crofelemer liquid formulation.

What is the clinical status of Jaguar Health's (JAGX) crofelemer program for intestinal failure?

Crofelemer is in an investigator-initiated proof-of-concept study for pediatric IF. According to the company, patients have been treated for more than one year with observed PS reductions in the trial.

What market opportunity did Jaguar Health (JAGX) cite for SBS and intestinal failure?

Jaguar cited an estimated global market for SBS, including IF, of about $8.0 billion by 2033. According to the company, this figure frames the potential commercial opportunity for treatments addressing IF.

What should investors know about the evidence supporting crofelemer's benefit in IF for JAGX shareholders?

Current evidence is from an investigator-initiated proof-of-concept trial with preliminary PS reductions. According to the company, results are promising but are early-stage and pending broader presentation and peer review.